| Identification | Back Directory | [Name]
N-[(5Z)-5-[(E)-3-(furan-2-yl)prop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzenesulfonamide | [CAS]
861123-84-4 | [Synonyms]
Benzenesulfonamide, N-[5-[3-(2-furanyl)-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidinyl]-
CU-3 5-(3-(2-Furyl)prop-2-enylidene)-3-
[(phenylsulfonyl)amino]-2-thioxo-1,3-thiazolidin-4-one
N-[(5Z)-5-[(E)-3-(furan-2-yl)prop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzenesulfonamide | [Molecular Formula]
C16H12N2O4S3 | [MDL Number]
MFCD07197018 | [MOL File]
861123-84-4.mol | [Molecular Weight]
392.47 |
| Hazard Information | Back Directory | [Description]
CU-3 is a novel potent and selective diacylglycerol kinase alpha (DGKalpha) inhibitor, attenuating cancer cell proliferation and simultaneously enhancing immune responses including anti-cancer immunity. |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|